CLAIMS

1. A process of conducting high throughput HPLC comprising:

    a) dropping containers of pre-weighed samples into plastic bottles;

    b) adding solution to each set of container and bottle via a bottle top dispenser;

    c) shaking each set of plastic bottle, container, and solution until sample is dissolved;

    d) centrifuging each set of plastic bottle, container, and solution;

    e) loading an aliquot of supernatant from the centrifuge step onto an HPLC column; and

    f) running the column with a mobile phase.

2. The process of claim 1, wherein the containers of step a) are vials.

3. The process of claim 1, wherein the plastic bottles of step a) are HDPE bottles.

4. The process of claim 1, further comprising correlating the results from the process of claim 1 to process analytical technique (PAT) measurements for continuous manufacturing.

5. The process of claim 4, wherein continuous manufacturing is for a pharmaceutical composition.

6. The process of claim 5, wherein the pharmaceutical composition is a tablet.

7. The process of claim 6, wherein the tablet is for the treatment of a cystic fibrosis transmembrane conductance regulator (CFTR) mediated disease.

8. The process of claim 7, wherein the CFTR mediated disease is cystic fibrosis.

9. The process of claim 6, wherein the tablet comprises two active pharmaceutical ingredients (API).

10. The process of claim 9, wherein one API is a cystic fibrosis (CF) corrector.

11. The process of claim 9, wherein one API is a CF potentiator.

12. The process of claim 9, wherein one API is a CF corrector and the other API is a CF potentiator.

13. The process of claim 9, wherein one API is



14. The process of claim 9, wherein one API is



15. The process of claim 9, wherein one API is



and the other API is



16. The process of claim 15, wherein

 is in Form I, and

 is substantially amorphous in the form of a soliddispersion.